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Role of cholinergic anti-inflammatory pathway in regu-
lating host response and its interventional strategy for
inflammatory diseases
WANG Da-wei 王大伟, ZHOU Rong-bin 周荣斌 and YAO Yong-ming 姚咏明*
The cholinergic anti-inflammatory pathway (CAP) is a
neurophysiological mechanism that regulates the immune
system. The CAP inhibits inflammation by suppressing
cytokine synthesis via release of acetylcholine in organs of
the reticuloendothelial system, including the lungs, spleen,
liver, kidneys and gastrointestinal tract. Acetylcholine can
interact with α7 nicotinic acetylcholine receptors (α7
nAchR) expressed by macrophages and other cytokine pro-
ducing cells, down-regulate pro-inflammatory cytokine syn-
thesis and prevent tissue damage. Herein is a review of the
neurophysiological mechanism in which the CAP regulates
inflammatory response, as well as its potential interventional
strategy for inflammatory diseases.
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Adequate inflammatory response initiated by in-fection and injury can eradicate the invadingpathogen and enhance wound healing. If the
inflammatory response is excessive, it will cause
cytokine overproduction which induces general tissue
damage and organ dysfunction. Excessive cytokine
production and release are characteristics of chronic
or uncontrolled inflammatory responses and primarily
related to the pathology of many diseases, including
sepsis, rheumatoid arthritis, Crohn’s disease and other
autoimmune diseases.1 Thus, inhibiting pro-inflamma-
tory cytokines is beneficial to prevent the occurrence
and progress of uncontrolled inflammatory responses.
For instance, experimental therapies that neutralize pro-
inflammatory cytokines, including monoclonal anti-tu-
mor necrosis factor (TNF) antibodies, interleukin (IL)-1
receptor antagonists and TNF-receptor fusion proteins,
are successfully used in rheumatoid arthritis, Crohn’s
disease, ankylosing spondylitis and psoriasis. Recent
studies have identified high mobility group box 1 pro-
tein (HMGB1) as an important late inflammatory me-
diator in sepsis and several inflammatory disorders. Anti-
HMGB1 therapeutics are successful in reducing multi-
organ injuries and improving survival in inflammatory
disease models.2
Anti-inflammatory mechanisms include the release
of glucocorticoids, anti-inflammatory cytokines such as
IL-10 and transforming growth factor-beta (TGF-β), and
soluble receptors which neutralize the activity of
cytokines. Recent studies found that vagus nerve-me-
diated cholinergic anti-inflammatory pathway (CAP) can
effectively regulate systemic inflammatory response.
This article reviewed the neurophysiological mechanism
in which the CAP regulates inflammatory response, as
well as its potential interventional strategy for inflam-
matory diseases.
Cholinergic anti-inflammatory pathway
The vagus nerve, in addition to its classically as-
signed function of controlling heart rate, hormone
secretion, gastrointestinal peristalsis and digestion, may
also be involved in regulating pro-inflammatory cytokines
(e.g. TNF-α) release. Even when circulating cytokine
levels are low, vagus nerve can detect peripheral
inflammation. Inflammatory signals to central nervous
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system via afferent vagus nerve activate CAP mediated
by efferent vagus nerve, which regulates cytokine pro-
duction and balances inflammatory response (Fig.1).
Peripheral inflammatory mediators activate afferent
vagus nerve signals,3 which are transmitted to medulla,
locus ceruleus, hypothalamus and dorsal motor nucleus
of  v agus.  Then adenohypophysi s secretes
adrenocorticotriphic hormone (ACTH), which increases
systemic glucocorticoid levels so as to inhibit pro-in-
f lammatory cytokine synthesis.  Meanwhile,
melanotropin induced by inflammation can also sup-
press cytokine synthesis. Ascending sensory fibers of
the vagus nerve synapses in the nucleus tractus soli-
taries (NTS) and preganglionic vagus nerve fibers, that
is CAP,4 are originated from dorsal motor nucleus
(DMN). Anti-inflammatory signals in vagal efferent nerve
fibers arrive at the reticuloendothelial system, includ-
ing the spleen, liver, heart, kidneys and gastrointesti-
nal tract. Acetylcholine released from vagus interacts
with α7 nicotinic acetylcholine receptors (α7 nAchR)
expressed by macrophages and other cytokine produc-
ing cells to inhibit cytokine production. The intracellu-
lar mechanisms in which cholinergic stimulation blunts
cytokine production are not completely clear, but cur-
rent study suggests that the CAP acts at both the tran-
scriptional and post-transcriptional levels via Janus ki-
nase (JAK) signal transducer and activator of transcrip-
tion (STAT) and nuclear factor kappa B (NF-κB)
pathways.
Given the short half-life of acetylcholine, cholinergic
modulation of immune cell activation most likely requires
close contact. Although macrophages are found in close
anatomical apposition to cholinergic fibers in the intes-
tine and spleen, there is no evidence that parasympa-
thetic neurons indeed innervate macrophages.5 It re-
mains to be elucidated whether acetylcholine released
from vagus nerve termini actually reaches the immune
cells, and if so, in what quantities.
Components of the cholinergic anti-inflammatory
pathway
Vagus nerve    Vagus nerve-derived cholinergic sig-
nals provide continuous neurological modulation of
cytokine synthesis to limit the magnitude of the im-
mune response. TNF-α, a major inflammatory media-
tor in endotoxemic hypotension, could be markedly in-
hibited during endotoxemic shock in rats by vagus nerve
stimulation (VNS).6 Consistently, surgical or chemical
vagotomy can repress the activity of vagus nerve, which
may lead to the increase of TNF-α release and septic
shock. Thus, vagus could be identified as a physiologi-
cal anti-inflammatory system controlling immune
reaction.
Vagus nerve signaling inhibits cytokine activities and
improves disease endpoints in experimental models of
sepsis, ischemia/reperfusion injury, hemorrhagic shock,
myocardial ischemia, ileus, experimental arthritis and
pancreatitis. However, VNS does not stimulate an in-
crease in either corticosteroid or IL-10 responses.
Therefore, anti-inflammatory effects of vagus nerve could
not be attributed to anti-inflammatory humoral
mechanisms. Interestingly, the dissociability and lower
Fig. 1. The cholinergic anti-inflammatory pathway.
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activation threshold of vagal anti-inflammatory signal-
ing suggest that the A fibers, which have the lowest
activation threshold and do not appear to participate in
heart rate regulation, may play the role of cholinergic
anti-inflammatory fibers.7
Splenic nerve    Catecholaminergic nerve termi-
nals are found adjacent to splenic macrophages in the
red pulp and the marginal zone which are the major
sources of splenic TNF-α during endotoxemia. Surgi-
cal ablation of the splenic nerve and catecholamine
depletion by reserpine abrogate the TNF-suppressive
effect of VNS, which indicates that splenic nerve are
required for functional inhibition of TNF-α production
by VNS. Thus, the CAP regulates TNF-α production
in discrete macrophage populations via two serially con-
nected neurons: one preganglionic, originating in the
dorsal motor nucleus of the vagus nerve, and the other
postganglionic, originating in the celiac superior me-
senteric plexus, and projecting in the splenic nerve.8 It
is possible that acetylcholine released by the vagus
nerve acts on α7 expressed in the ganglia of the ce-
liac superior mesenteric plexus to modulate splenic
nerve function, playing an anti-inflammatory role.
Furthermore, acetylcholine may be released from
spleen by stimulation of the splenic nerve. So it is pos-
sible that catecholaminergic signals via the splenic nerve
enhance acetylcholine levels in the spleen, which at-
tenuate cytokine production by signaling through α7
nAchR.
Spleen    The spleen is an important source of
systemic TNF-α following septic challenge. VNS could
inhibit serum TNF-α levels but fails to inhibit TNF-α
formation in splenectomized animals during lethal
endotoxemia. In septic animals, administration of nico-
tine that mimics vagus nerve stimulation, decreases
pro-inflammatory cytokine production and lethality, while
splenectomy could reverse the protective effects of
nicotine. These findings indicate that the spleen is critical
to the protective response of the cholinergic pathway.9
Selective lesion of the common celiac nerve abolishes
TNF-α suppression by VNS, suggesting that the cho-
linergic pathway functionally links to the spleen via this
branch of the vagus nerve.
α7 nAchR    nAChR is composed of five receptor
subunits, including α1-α10, β1-β4, γ, δ and ε,
which form ligand-gated ion channels.10 According to
their physiological distribution, nAChRs are classified
as muscle nAChRs (consisting of α1, β1, γ, δ, and
ε subunits) or neuronal nAChRs (consisting of α2-α10
and β2-β4). The neuronal nAChRs are further sub-
classified into either homomeric nAChRs (e.g. α7 or α9)
or heteromeric nAChRs (including combinations of α
and β subunits, e.g. α3β2). In neurons, α7 nAChR
assembles as a homopentamer composed of five indi-
vidual α7-subunits which form a central pore with ligand
binding at subunit junctions responsible for changes in
the state of the receptor. α7 homopentamer is highly
permeable for Ca2+ in preference to Na+ and has low
sensitivity to acetylcholine. The identity of the α7 sub-
unit expressed on macrophages is confirmed by clon-
ing and sequencing, and is identical to the α7 subunit
expressed in neurons. Western blot analysis reveals
that the α 7 subunit protein expressed in macroph-
ages has a relative molecular mass of 55 kDa, identi-
cal to that described in neurons. However, whether the
structure and functional activity of non-neuronal α 7
nAChR is the same as that of neuronal α7 nAChR
remains to be elucidated.
It has been reported that acetylcholine attenuates the
release of cytokines (TNF-α, IL-1β, IL-6 and IL-8), but
not the anti-inflammatory cytokine IL-10, in lipopolysac-
charide (LPS)-stimulated human macrophage cultures.6
The effects of acetylcholine are mediated by α -
bungarotoxin-sensitive nAChR, which is confirmed as
α7 nAChR by subsequent studies.11 VNS inhibits TNF-α
synthesis in wild-type mice, but fails to inhibit TNF-α
synthesis in α7-deficient mice. Thus, α7 subunit is
essential for inhibiting cytokine synthesis by the CAP.11
This viewpoint is further confirmed by the fact that VNS
inhibits TNF-α synthesis without the involvement of
muscarinic receptors in immune cells.12
α7 receptor is widely expressed in endothelial cells,
enterocytes, T lymphocytes, B lymphocytes, dendritic
cells, monocytes, macrophages, neutrophils and mi-
croglia cells. Therefore, α7 receptor agonists have sys-
temic anti-inflammatory effects on various organs and
tissues. Nevertheless, VNS acts through α7 nAChRs
on macrophages, there are no data demonstrating that
α7 receptors on other cell types are regulated by va-
gus nerve.
Central muscarinic receptor     Intracerebroventricular
administration of muscarine receptor agonists signifi-
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cantly reduces serum TNF-α levels during endotoxemia.
It also increases instantaneous heart rate variability,
an indicator of enhanced vagus nerve activity in the
periphery. These observations indicate that muscarinic
brain networks regulate the cytokine-controlling func-
tion of vagus nerve. Vagus nerve fiber could be stimu-
lated by CNI-1493, a tetravalent guanylhydrazone mol-
ecule that down-regulates systemic inflammation. Anti-
inflammatory effects of CNI-1493 are also mediated by
central muscarine receptors. In addition, galantamine,
an acetylcholinesterase inhibitor, could pass through
blood-brain barrier, inhibit brain acetylcholinesterase and
thus faci li tate brain cholinergic transmission.
Galantamine suppresses systemic inflammation dur-
ing endotoxemia through a central muscarinic recep-
tor-mediated and vagal- and α7 nAChR-dependent
mechanism.12
Controlling inflammation through the cholinergic
anti-inflammatory pathway
  Electrical VNS and/or α7 nAChR agonists have
been successfully applied in models of inflammatory
diseases, including endotoxaemia, sepsis, ischaemia/
reperfusion injury, haemorrhagic shock, subcutaneous
and gastrointestinal inflammation and pancreatitis.
Sepsis    VNS can reduce excessive inflammation
and acute reaction to sepsis.  During lethal
endotoxaemia, VNS inhibits TNF-α synthesis in liver,
attenuates peak serum TNF-αlevels and prevents the
development of shock. In contrast, vagotomy signifi-
cantly increases the levels of serum and liver TNF-α.6
VNS can also prevent the development of cecal ligation
and puncture (CLP)-induced hypotension, alleviate he-
patic damage and reduce the plasma TNF-α release.
Moreover, transcutaneous VNS reduces systemic TNF-α
levels during lethal LPS challenge, inhibites HMGB1
levels and improves survival in mice with polymicrobial
sepsis.7
  Anti-inflammatory effects of agonists for α7 nAChR
in experimental sepsis have also been confirmed.
Nicotine, a highly efficient nAChR agonist, inhibits
HMGB1 release of macrophages induced by either LPS
or TNF-αvia activation of α7 nAChR; in vivo, nicotine
treatment attenuates serum HMGB1 levels and improves
survival in CLP models. These effects can be attributed
to acute reduction of HMGB1 and pro-inflammatory
cytokines, rather than effects on bacterial outgrowth
when mice receive nicotine 24 hours after CLP.13 An-
other report reveals that experimentally induced sys-
temic inflammation using endotoxin in other healthy
human volunteers can be reduced by pretreatment with
transcutaneous nicotine.14 Cotinine is a stable nicotine
catabolite. Pretreatment of monocytes with cotinine
shiftes the inflammatory response to LPS to an IL-10-
dominated anti-inflammatory profile which is initiated
by engagement of the monocytic α7 nAChR.15 GTS-21,
a selective α7 nAChR agonist, significantly inhibits
serum HMGB1 levels in CLP mice and improves survival.
Also, GTS-21 strongly inhibits LPS-induced TNF-α
release into the peritoneal cavity and attenuates the
influx of neutrophils into peritoneal fluid upon adminis-
tration of LPS, and it is independent of its effect on
TNF-α release. Choline is a precursor in the biosyn-
thesis of acetylcholine and a selective natural α7
nAChR agonist. Recent study has shown that choline
can suppress TNF-α release from LPS-activated mac-
rophage-like cells, reduce systemic TNF-α levels dur-
ing endotoxaemia through an α7 nAChR-mediated
mechanism and suppress HMGB1 release in mice with
severe sepsis. The anti-inflammatory effect of vagus
nerve in lungs is limited, however, anti-inflammatory
effect of α7 nAChR agonists in lungs is obvious. For
example, nicotine, choline and PNU-282987 (a specific
α7 agonist) reduce acid-induced acute lung injury; lo-
cal administration of GTS-21 inhibits TNF-α release
in lungs during LPS-induced sepsis.
  Interestingly, vagus nerve firing and α7 nAChR ac-
tivation have a detrimental effect on host defense against
bacteria in septic animals. Pretreatment with nicotine
during septic peritonitis results in a reduction of local
and systemic inflammation, but increases lethality,
because of a decrease in bacterial clearance and en-
hanced dissemination of bacteria.17 A possible expla-
nation is that host defense in septic peritonitis is a deli-
cate balance between pro-inflammatory pathways in-
tended to eliminate bacteria and anti-inflammatory path-
ways intended to prevent systemic inflammation, and
any imbalance in pro- or anti-inflammatory mediators
might be harmful. Accordingly, 20 hours after E. coli
challenge, α7 nAChR knock-out mice display an ac-
celerated bacterial clearance as compared with wild-
type mice. As a result of reduced bacterial loads, α7
nAChR knock-out mice have reduced numbers of infil-
trating neutrophils and lower circulating cytokine levels
at that time point.18
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Studies demonstrate that inflammatory response in
sepsis can be controlled via activation of the central
cholinergic system. CNI-1493 administered via the
intracerebroventricular route is more effective in sup-
pressing LPS-induced TNF-α release and shock as
compared with intravenous dosage. Such protective ef-
fects require an intact vagus nerve. Similarly, intrave-
nously administered oxytocin can reduce the neuroen-
docrine and cytokine response to bacterial LPS by in-
creasing the excitability of central vagal neurons and
CAP.19 Moreover, ghrelin, a novel orexigenic hormone,
is produced predominately in the gastrointestinal
system, and intravenously administration of exogenous
ghrelin markedly reduces TNF-α and IL-6 levels through
central activation of vagus nerve in sepsis.20
  Cholinesterase inhibitors can also control the in-
flammatory response in experimental sepsis. Cholinest-
erase inhibition significantly improves survival if admin-
istered directly after induction of sepsis, but no trend to
a reduction in mortality is achieved when treatment is
delayed.21 Moreover, the mortality is increased when
higher doses of  cholinesterase inhibitors are
administered. These drugs presumably act by raising
and prolonging the profile of acetylcholine via an inhibi-
tory effect on the esterase.
 Patients with sepsis display evidence for activa-
tion of the coagulation system, which in its most ex-
treme form can result in disseminated intravascular
coagulation. Endothelial cell activation is critical in this
process. Evidence shows that cholinergic stimulation
blocks endothelial cell activation and leukocyte
recruitment; VNS inhibits activation of coagulation and
fibrinolysis during endotoxemia in rats. Therefore, CAP
has impacts on inflammatory process and the coagu-
lant/anticoagulant balance in sepsis.
Hemorrhagic shock    Hemorrhagic shock initiates
an inflammatory response characterized by the
upregulation of cytokine expression. These changes
contribute to end-organ damage and resultant dysfunc-
tion after shock. Application of constant voltage pulses
to the caudal vagus ends increases survival time, re-
verts the marked hypotension, blunts the augmented
NF-κB activity and inhibits TNF-α synthesis in ani-
mal models of acute hypovolemic hemorrhage. The pro-
tective effects of VNS are mediated through nicotinic
receptors.22 The melanocortin ACTH (1-24) suppresses
the NF-κB-dependent systemic inflammatory response
triggered by hemorrhage, and reverses shock condition.
And bilateral cervical vagotomy prevents the life-saving
effect of ACTH (1-24).23 The data suggest that ACTH(1-24)
acts by brain activation of the CAP. It has been demon-
strated that ingestion of dietary fat stimulates chole-
cystokinin receptors and leads to attenuation of the
inflammatory response. Vagotomy and administration
of antagonists for cholecystokinin as well as nicotinic
receptors significantly blunt the inhibitory effect of high-
fat enteral nutrition on hemorrhage-induced TNF-α and
IL-6 release.24 These data revealed that nutritional stimu-
lation of cholecystokinin receptors inhibits inflamma-
tion via the vagus nerve. Therefore, intestinal
hyporesponsiveness to dietary antigens may be asso-
ciated with tonic anti-inflammatory effects of vagus
nerve.
Ischemia-reperfusion injury    Ischemia-
reperfusion injury is a pathologic event characterized
by tissue damage. It is mediated by TNF-α and other
cytokines that activate complement and proteases and
stimulate fibrinolysis, degranulation of white blood cells,
and free radical production. During reperfusion injury in
a standard model of aortic occlusion, VNS significantly
attenuates shock and inhibits TNF-α levels in serum,
heart and liver.25 Additionally, in a splanchnic artery oc-
clusion shock model, VNS could increase survival rate,
revert the marked hypotension, decrease hepatic TNF-α
mRNA, reduce plasma TNF-α, ameliorate leukopenia,
and decrease leukocyte accumulation in ileum and
lungs. Chlorisondamine, an irreversible peripheral nico-
tinic receptor-blocking agent, can abate the effects of
VNS. Thus, the anti-shock mechanism of VNS might
be that acetylcholine, released by vagal ends, diffuses
in liver resident macrophages before being completely
hydrolyzed and blunts the inflammatory cascade.
Furthermore, VNS strongly decreases the high inci-
dence of severe arrhythmias and lethality, reduces the
increase in free radical blood levels and left-ventricle
histologic alterations during an experimental model of
ischemic heart disease. Treatment with the melanocortin
produces the same protective effects of VNS through
brain activation of CAP.26 Cholinergic agonists also have
a protective effect in ischaemia/reperfusion injury. For
instance, nicotine or GTS-21 can attenuate renal
dysfunction, tubular necrosis, TNF-α production and
leukocyte infiltration induced by renal ischemia.27 The
reduction in α7 nAChR expression following nicotine
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treatment may represent an important protective
mechanism. The increase in α7 protein after renal is-
chaemia/reperfusion injury may augment the calcium
influx, which is a major mechanism of cell injury and
death during ischaemia/reperfusion injury.28 Recent
study reveals that ghrelin administration down-regulates
pro-inflammatory cytokine expression, reduces neutro-
phil infiltration, ameliorates intestinal barrier dysfunction,
attenuates organ injury and improves survival after gut
ischaemia/reperfusion injury. Beneficial effects of ghrelin
on gut ischaemia/reperfusion injury are mediated through
the central activation of the CAP.29 Finally, Huperzine
A, a selective acetylcholinesterase inhibitor, exhibits
anti-inflammatory and neuroprotective effects against
transient focal cerebral ischemia-induced brain injury
created by middle cerebral artery occlusion. The pro-
tection mechanism involves the inhibition of acetyl-
cholinesterase activity and activation of nAChR in central.30
Pancreatitis     A lot of clinical and experimental
evidences suggest that cytokines play a key role in the
pathogenesis of local and systemic complications of
acute pancreatitis. In mouse model of pancreatitis in-
duced by cerulein, vagotomy exacerbates inflamma-
tion and this effect is counteracted by pretreatment with
nicotine or GTS-12.31 These results imply an important
role for the nAChR α7 subunit in mediating the cholin-
ergic anti-inflammatory effect.
Ileus    Ileus is a complication of abdominal surgery
or trauma characterized by gastrointestinal hypomotil-
ity and delayed gastric emptying. An enteric molecular
inflammatory response impairs local neuromuscular
function, activates neurogenic inhibitory pathways and
inhibits motility of the entire gastrointestinal tract. In
animal models of postoperative ileus, VNS or adminis-
tration of nicotine attenuates hypomotility and reduces
cytokine production through an α7 nAChR-mediated
activation of JAK2/STAT3 pathway.5 Similarly, pretreat-
ment with AR-R17779, a selective α7 nAChR agonist,
could prevent delayed gastric emptying and reduce in-
flammatory cell recruitment. Moreover,  AR-R17779 and
nicotine reduce pro-inflammatory cytokine formation in
peritoneal macrophages and the latter is more effective,
which implies that nicotinic inhibition of macrophage
activation may involve other receptors in addition to α7
nAChR.32
Colitis    Colitis are characterized by pro-inflamma-
tory cytokines, tissue damage and loss of neuron in
inflamed mucosa, implying that CAP may be destroyed
during the process of inflammatory response.
  Cholinergic agonist could inhibit colonic inflamma-
tory response. For instance, nicotine decreases the
levels of pro-inflammatory mediator in colonic mucosa
during experimental colitis. It also has beneficial effects
on the patients with ulcerative colitis, but clinical us-
age of nicotine is limited because of its side effects.
Anabaseine, a cholinergic agonist, could reduce tis-
sue damage and decrease myeloperoxidase activity and
TNF-α level in colon of mice with colitis, whereas nico-
tinic receptor antagonist could reverse the above-men-
tioned effects.33 Moreover, depression induced in mice
with previously established colitis, can exacerbate the
reactivation of colitis and the harmful effects of depres-
sion can be attenuated by choline-chloride, a specific
α-7 agonist.34 The vagus nerve also has a tonic effer-
ent cholinergic anti-inflammatory effect in acute experi-
mental colitis35 and chronic colitis36. Colitis induced by
dextran sodium sulfate is more severe in vagotomized
mice compared with sham-operated mice. As the va-
gus nerve does not innervate the distal colon and rectum,
the areas are usually affected in patients with inflam-
matory bowel diseases. The anti-inflammatory effect of
vagus nerve can be possibly clarified by the role of the
spleen in exerting the anti-inflammatory effect of vagus
nerve signaling or by changes in autonomic (para)sym-
pathetic balance.34 Furthermore, acetylcholinesterase
inhibitors could effectively modulate the acute colonic
inflammation associated with dinitrobenzene sulfonic
acid-induced colitis.
  Interestingly, vagotomy has little pro-inflammatory
effects in the chronic colitis induced by transfer of
CD4
+CD62L+ T lymphocytes into severe combined im-
munodeficiency disease mice. That may be due to the
unknown effects of vagus nerve on T cells.37 In another
study, experimental colitis was aggravated in nAChR
α5 subunit deficient mice, suggesting that not only
the α7 nAchR, but also other nAChR subunits could
participate in the vagus modulation of colitis in mice.38
Alzheimer disease    Alzheimer disease is char-
acterized by inflammatory process in the senile plaques
and surrounding glia, with enhanced expression of acute
phase proteins, in which a local inflammatory response
is sustained by microglial cells. Activated microglial cells
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could cause neuronal damage via liberation of free radi-
cals as well as cytokines and toxic factors. In an in
vitro study, it revealed that activation of microglial cells
by nicotine dose-dependently reduces the LPS-induced
release of TNF-α. Nicotine can also activate micro-
glial α7 nAChRs, drive a phospholipase C/IP3 path-
way and modulate cell  activ ation toward a
neuroprotective role. Moreover, nicotine decreases β-
amyloid peptide, a hallmark of Alzheimer disease, via
the activation of α7 nAChRs through mitogen-activated
protein kinase, NF-κB and c-myc pathways.39 Epide-
miological studies indicate that nicotine might be pro-
tective against the development of Alzheimer disease.
Nicotine-mediated neuroprotection in these studies pro-
vide a mechanistic basis for the potential development
of drug target for treating Alzheimer disease.
Myocardial infarction    Within minutes of acute
myocardial infarction, pro-inflammatory cytokines in-
crease in the brain, heart, and plasma. Francis et al40
noted that vagotomy one hour before ventricular is-
chaemia in rats had anti-inflammatory effects, e.g. di-
minishing the post-infarction TNF-α increase in
myocardium. A possible explanation is that vagotomy
has substant i al  e f f ects on hear t  ra te  and
haemodynamics which may have determined the early
response to vagotomy. The other explanation might be
the distinction between acute (within minutes) and
chronic (within days and months) effects of vagotomy
in animals.41 It is demonstrated that in a rat model of
endotoxaemia, vagotomy increases plasma TNF-α lev-
els when performed 3 days before LPS administration.
In contrast, vagotomy paradoxically diminishes plasma
TNF-α levels when performed 30 minutes directly be-
fore LPS administration (which seems to be due to the
release of acetylcholine by nerve endings during peri-
vagotomy mechanical manipulations on vagal nerve).
Arthritis    A possible anti-inflammatory role for CAP
in arthritis was suggested by studies that showed an
anti-inflammatory effect of cholinergic stimulation
(including VNS, cholinergic agonists) on carrageenan-
induced paw inflammation and carrageenan air pouch
model.42 Subsequent study showed that unilateral cer-
vical vagotomy exacerbated collagen-induced arthritis
and the treatment with an α7 nAChR agonist (AR-
R17779) ameliorated the disease.43 Consistently, a
marked increase was found in clinical arthritis scores
and synovial inflammation in α7-deficient mice com-
pared with wild-type littermates in both acute and
chronic phase of the disease. Underscoring the impor-
tance of α7 nAChR in rheumatoid arthritis, nicotine
and α7 nAChR-specific agonists (PNU-282987) can
modulate the inflammatory response of fibroblast-like
synoviocytes in vitro for the patients with rheumatoid
arthritis.44 Moreover, in vivo study showed that AR-
R17779 had an anti-inflammatory effect on collagen-
induced arthritis.43  AR-R17779 poorly crosses the blood-
brain barrier, suggesting that the anti-inflammatory ef-
fects of this agonist are probably due to the peripheral
stimulation of α7 nAChR. It has recently been shown
that VNS can suppress the development of collagen-
induced arthritis in rats.45 The reduction of inflamma-
tion observed following VNS may be attributable to the
down-regulation of cytokine production by the reticu-
loendothelial system and redirection of leukocytes traf-
ficking away from the periphery.
Others    In Fas-induced fulminant hepatitis, vago-
tomy triggers exacerbation of hepatitis, whereas supple-
mentation with α7 nAChR agonists dose-dependently
inhibits this detrimental effect of vagotomy. Thus, the
hepatic vagus nerve appears to play an important role
in attenuating Fas-induced hepatocyte apoptosis
through α7 nAChR.46 In an animal model of ricin
poisoning, nicotine administration could attenuate cel-
lular oxidative stress, reduce serum levels of TNF-α
and markers of kidney as well as liver dysfunction, and
decrease mortality.47 Moreover, the combined signal-
ing by the nicotine and estrogen synergistically reduces
experimental chronic bladder inflammation, which can
be measured by macrophage infiltration and up-regula-
tion of IL-6 expression in the bladder.48 Finally, VNS is
followed by anti-inflammatory reactions within myocar-
dial tissue in a canine model of chronic heart failure.
Relationship between vagus nerve activity and in-
flammatory diseases
Clinical research implicates a significant correlation
between depressed vagus nerve activity and increased
severity of inflammatory diseases including sepsis, rheu-
matoid arthritis, lupus, sarcoidosis, inflammatory bowel
diseases. For example, HMGB1 is a cytokine impli-
cated in the pathogenesis of rheumatoid arthritis. Se-
rum HMGB1 levels in patients with rheumatoid arthritis
were inversely related to RR interval variability (RRV,
an index of vagus nerve activity).49 Lower vagal nerve
activity also contribute to the increased incidence of
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sudden death observed in rheumatoid arthritis. Data also
show that Alzheimer disease and other brain degen-
erative disorders are characterized by cholinergic defi-
ciency and decreased vagus nerve activity. In addition,
vagally mediated heart rate variability is inversely cor-
related with inflammatory markers. For instance, an
inverse relationship in apparently healthy humans be-
tween an index of vagally mediated cardiac activity and
C-reactive protein in vivo has been demonstrated after
controlling a wide range of covariates including an in-
dex of sympathetic nervous system activity.50 H. pylori
infection has protective effects against gastroesoph-
ageal reflux disease and one mechanism might be that
H. pylori infection in gastric mucosa induces a T helper
1-like immune response and production of pro-inflam-
matory cytokines which elevate the vagus nerve activ-
ity to alleviate oesophageal inflammation, and lead to a
decrease in reflux-induced oesophageal injury and
dysfunction.51 Interestingly, increased vagal tone is
associated with increased mortality and poor outcome
in patients with traumatic brain injury. Sustained ef-
fects of CAP in patients with traumatic brain injury could
severely impair the body’s ability to combat infection
and cause immune paralysis, which is responsible for
the increased mortality.52 Finally, to be emphasized, a
causal relationship between depressed vagus nerve
activity and increased inflammatory disease severity
has not been established.
Various therapeutics of inflammatory diseases could
increase vagal nerve activity. For example, acupuncture,
an adjunct therapy of conventional medical treatment
for a number of chronic inflammatory and autoimmune
diseases can calm the mind, slow down the heart rate
and stimulate gastric mobility.53 The systemic anti-in-
flammatory actions of traditional and electro-acupunc-
ture are directly or indirectly mediated by the efferent
vagus nerve activation and inflammatory macrophage
deactivation. Meanwhile, complex behavior originated
in higher brain centers, such as hypnosis, meditation,
prayer, guided imagery, biofeedback, and the placebo
effect, can directly influence outflow through the vagus
nerve and exert anti-inflammatory effects. Exercise re-
duces levels of TNF-α and other cytokines, increases
vagus nerve activity and protection against cardiovas-
cular disease and type II diabetes.54 Conversely, obe-
sity is characterized by diminished vagus nerve output
and elevated cytokine levels, both of which involve in
the pathogenesis of  insul in resistance and
atherosclerosis. Clinical studies have denmonstrated
that high-fat nutrition could effectively increase vagus
nerve activity, reduce the production of inflammatory
mediators and improve inflammatory bowel disease,
rheumatoid arthritis and cardiovascular diseases. These
effects of high-fat nutrition may be related to the activa-
tion of CAP, just like the anti-inflammatory mechanism
in animals.
Conclusion
The diffusible anti-inflammatory network, which in-
cludes glucocorticoids, anti-inflammatory cytokines and
other humoral mediators, is concentration gradient-
dependent, slow and nonintegrated. In contrast, CAP
is discrete and localized in tissues where invasion and
injury are typically originated. Compared with the rou-
tine biological pace of a typical, diffusible inflammatory
response (hours to days), neural signaling is lightning
fast. In addition, this pathway can inhibit various pro-
inflammatory cytokines and overcome the limitation of
anti-inflammatory agents targeting single mediator.
Thus, it might be beneficial to sepsis in which multiple
inflammatory mediators participate in the excessive in-
flammatory response. VNS has shown better control of
depression with marginal side effects and it might pro-
vide an advantage for the treatment of chronic inflam-
matory disorders such as rheumatoid arthritis. α7
nAChR is a pharmacological target for inflammation in
the CAP. Future studies are needed to evaluate the
potential use of specific α7 nAChR agonists and de-
termine their effects on physiological variables includ-
ing blood pressure, respiratory status and renal function.
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